Service médecine interne-Hôpital Tenon
Paris, 75020, France
Location status: Recruiting
NCT Number: NCT06354322
Patients with autoinflammatory diseases (AID) have recurrent episodes of systemic inflammation accompanied by nonspecific elevation of blood inflammation markers typically absent between attacks. A complication of autoinflammatory diseases is AA amyloidosis, which can lead to renal failure and dialysis. Advances in genetic analysis have led to the identification of new autoinflammatory diseases and thus new pathophysiological pathways.
However, genetic analyses are sometimes confronted with results that are difficult to interpret. These are the Variants of Unknown Significance, for which genetic analysis alone does not allow to determine if the genetic mutation is responsible for the symptoms.
genetic analysis sometimes has limitations in the diagnosis of AID which can only be overcome by pathophysiological studies of the variants found.
Interested in participating?
Request Info3 year–80 year
All sexes
Observational
Paris, 75020, France
Location status: Recruiting
The study aim to explore variants of undetermined significance in major and minor patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity.
National multicenter research: internal medicine department of Tenon Hospital, pediatric department of Versailles Hospital and pediatric dermatology department of Necker Enfants Malades Hospital in Paris
Samples will be collected at the inclusion visit or at subsequent visits of the patient to the department during a blood draw performed as part of routine care by a registered nurse.
The total volume of the sample will be 24 mL per 6 month period maximum, and will not exceed In case of skin involvement of the auto-inflammatory disease, a skin biopsy may be performed as part of the patient's follow-up care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for patients to be studied:
Inclusion criteria
for control patients:
Exclusion criteria
Time frame: Up to 4 years
To explore variants of undetermined significance (VUS)in patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity.
Time frame: Up to 4 years
To improve the knowledge on the pathophysiology of Autoinflammatory Diseases: to determine the role of new inflammation pathways in AutoInflammatory Diseases
Time frame: Up to 4 years
Evaluate the role of other innate immune cells (neutrophils, mast cells...) and their mediators
Time frame: Up to 4 years
Improve knowledge of AA amyloidosis, a complication of autoinflammatory diseases
Contact information is provided by the study sponsor or research team.
Assistance Publique - Hôpitaux de Paris
Other
Physiopathological Investigation of Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis
Acronym: IPHYGENI MAI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06397001
AA Amyloidosis, AA amyloidosis
Rochester, Minnesota, United States
View Trial DetailsNCT02704065
AA Amyloidosis, AA amyloidosis
Bursa, Turkey (Türkiye)
View Trial DetailsNCT00059748
Autoinflammatory Disease, Connective Tissue Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06004349
Autoimmune Disease, Autoimmune Diseases
New York, United States
View Trial Details